Novo Nordisk to cap insulin prices in Minnesota settlement

In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...